Clinical trial
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus…
NCT00394277 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00394277 |
|---|---|
| Title | A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C |
| Official title | Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection… |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a, Ribavirin |
| Enrollment | 1,175 |
| Start date | Feb 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Oct 31, 2006 |
| Last update posted | Aug 3, 2010 |
| Countries | Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Netherlands, Poland, Puerto Rico, Romania, Russia and 3 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: